Medpace Holdings, Inc. (NASDAQ:MEDP) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, November 1st. Analysts expect Medpace Holdings to post earnings of $0.35 per share for the quarter. Medpace Holdings has set its FY17 guidance at $1.36-1.46 EPS.

Medpace Holdings (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, July 31st. The company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of $0.30 by $0.08. The business had revenue of $94.60 million for the quarter, compared to analyst estimates of $92.71 million. Medpace Holdings had a return on equity of 9.32% and a net margin of 5.37%. Medpace Holdings’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.45 EPS. On average, analysts expect Medpace Holdings to post $1.43 EPS for the current fiscal year and $1.64 EPS for the next fiscal year.

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) opened at 33.56 on Wednesday. The company’s 50-day moving average price is $32.53 and its 200-day moving average price is $29.79. Medpace Holdings, Inc. has a 12 month low of $21.76 and a 12 month high of $38.94. The company has a market cap of $1.33 billion, a price-to-earnings ratio of 59.08 and a beta of -0.86.

A number of research analysts recently commented on MEDP shares. Zacks Investment Research raised Medpace Holdings from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 5th. Jefferies Group LLC reissued a “hold” rating and issued a $31.00 target price (up previously from $30.00) on shares of Medpace Holdings in a research note on Wednesday, August 2nd. KeyCorp reissued a “hold” rating on shares of Medpace Holdings in a research note on Tuesday, October 17th. Robert W. Baird reissued a “hold” rating and issued a $32.00 target price on shares of Medpace Holdings in a research note on Monday, October 9th. Finally, Raymond James Financial, Inc. started coverage on Medpace Holdings in a research note on Friday, September 29th. They issued a “market perform” rating on the stock. Seven research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Medpace Holdings has a consensus rating of “Hold” and a consensus target price of $34.20.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at

In other news, major shareholder Medpace Limited Partnership sold 2,000,000 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $30.27, for a total transaction of $60,540,000.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 25.80% of the stock is currently owned by company insiders.

Medpace Holdings Company Profile

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.

Receive News & Ratings for Medpace Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc. and related companies with's FREE daily email newsletter.